FIGHT-302
FIGHT-302 set out to test whether the FGFR2 inhibitor pemigatinib should be used before chemotherapy in bile duct cancers driven by an FGFR2 fusion; the trial was stopped before it could answer the question.
Overview
Pemigatinib was approved in 2020 for previously treated cholangiocarcinoma with an FGFR2 fusion or rearrangement on the single-arm FIGHT-202 study. FIGHT-302 was the confirmatory phase 3 trial, randomising patients with untreated, unresectable or metastatic FGFR2-rearranged cholangiocarcinoma to pemigatinib or to gemcitabine and cisplatin, with progression-free survival as the primary endpoint.
The trial is recorded as terminated on ClinicalTrials.gov after enrolling 167 patients and has not reported an efficacy comparison, so the first-line question for FGFR inhibitors in this disease remains open.
Similar pages
not linked directly; found by shared links- TrialABC-06
Shares Biliary tract cancer (all types), Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma) and the tag subtype-trials.
- TrialABC-02
Shares Biliary tract cancer (all types), Gemcitabine + cisplatin, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
- TrialFIGHT-202
Shares Pemigatinib, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
- TrialBILCAP
Shares Biliary tract cancer (all types), Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
- Key paperFIGHT-202: pemigatinib for previously treated cholangiocarcinoma with FGFR2 fusions or rearrangements
- TermFGFR2 fusions and rearrangements
Shares Pemigatinib, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
- PairingGemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer
Shares Gemcitabine + cisplatin, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
- TrialKEYNOTE-966
Shares Gemcitabine + cisplatin, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).